One may not conclude that the drug is not showing efficacy
In prior conversations with management and the PR firm, I was led to believe if Bavi demonstrated any significant responses in the cancer protocol it would be PR'd. With respect to the Phase Ia trial, IMO, they announced the data immediately after the 12 week follow up was completed.